 Allergan Inc on Tuesday rejected a sweetened  billion bid from Valeant Pharmaceuticals International Inc and William Ackman and said it still wouldnt enter into negotiations The Irvine Calif maker of Botox said Valeants cashandstock offer significantly undervalues its prospects for growth It again called Valeants business model unsustainable and said Allergan shareholders dont want Valeant stock They
  